Brief: Northwest Biotherapeutics to voluntarily delist from Nasdaq
08/12/2016 01:00
Dec 7 (Reuters) - Northwest Biotherapeutics Inc NWBO.O
* Says desires to proceed with multiple phase 2 trials in
addition to completing its current phase 3 trial
* Nw bio announces decision to voluntarily withdraw from
Nasdaq listing and begin trading on otc market
* Says Nasdaq is expected to be suspended on or about
December 19, 2016
Source text for Eikon: urn:newsml:reuters.com:*:nPn1ZF5Pta
Further company coverage: NWBO.O
((Bangalore.newsroom@thomsonreuters.com;)) Dec 7 (Reuters) - Northwest Biotherapeutics Inc NWBO.O
* Says desires to proceed with multiple Phase 2 trials in
addition to completing its current Phase 3 trial
* NW Bio announces decision to voluntarily withdraw from
Nasdaq listing and begin trading on OTC Market
* Says Nasdaq is expected to be suspended on or about
December 19, 2016
Source text for Eikon: ID:nPn1ZF5Pta
Further company coverage: NWBO.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB